|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/28 | |||
| A61K 35/74 | |||
| A61P 35/00 |
| (11) | Number of the document | 3319635 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16734013.2 |
| Date of filing the European patent application | 2016-06-24 | |
| (97) | Date of publication of the European application | 2018-05-16 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-21 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2016/051893 |
| Date | 2016-06-24 |
| (87) | Number | WO 2016/207646 |
| Date | 2016-12-29 |
| (30) | Number | Date | Country code |
| 201511120 | 2015-06-24 | GB | |
| 201511121 | 2015-06-24 | GB |
| (72) |
AKLE, Charles, GB
BRUNET, Laura Rosa, GB
|
| (73) |
Immodulon Therapeutics Limited,
6-9 The Square Stockley Park, Uxbridge UB11 1FW,
GB
|
| (54) | A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY |
| A CHECKPOINT INHIBITOR AND A WHOLE CELL MYCOBACTERIUM FOR USE IN CANCER THERAPY |